Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system

被引:13
|
作者
Caberlotto, Laura [1 ]
Carboni, Lucia [1 ]
Zanderigo, Floriana [1 ]
Andreetta, Filippo [1 ]
Andreoli, Michela [1 ]
Gentile, Gabriella [1 ]
Razzoli, Maria [1 ]
机构
[1] GlaxoSmithKline Med Res Ctr, Neurosci CEDD, I-37135 Verona, Italy
关键词
Amphetamine-induced hyperlocomotion; Blood BDNF levels; Blood hormone levels; CRMP2; GSK3; inhibitors; Lithium; RESPONSE MEDIATOR PROTEINS; ELEMENT-BINDING PROTEIN; NEUROTROPHIC FACTOR; INDUCED HYPERACTIVITY; MOOD STABILIZERS; SODIUM VALPROATE; GROWTH-HORMONE; BETA-CATENIN; BRAIN; PHOSPHORYLATION;
D O I
10.1007/s00210-013-0893-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Glycogen synthase kinase (GSK3) is a constitutively active serine-threonine kinase associated to neurological and psychiatric disorders. GSK3 inhibition is considered a mediator of the efficacy of the mood-stabiliser lithium. This study aimed at comparing the central nervous system effect of lithium with the selective GSK3 inhibitors AZ1080 and compound A in biochemical, cellular, and behavioural tests. Collapsin response mediator protein 2 is a neuron-specific GSK3 substrate. Lithium, AZ1080, and compound A inhibited its phosphorylation in rat primary neurons with different pIC(50). After systemic treatments with lithium or GSK3 inhibitors to assess specific functional responses, phosphorylation was unchanged in adult rat brain, while it was strongly inhibited by GSK3 inhibitors in pups, differently from lithium. Lithium may exert neurotrophic effect by increasing brain-derived neurotrophic factor (BDNF) levels: in the present experimental conditions, lithium exerted opposite effects on plasma BDNF levels compared to GSK3 inhibitors, suggesting this effect might not be necessarily mediated by GSK3 inhibition alone. While plasma thyroid-stimulating hormone and luteinising hormone were not affected by lithium, they were decreased by selective inhibitors. GH and prolactin displayed similar responses towards reduction. Follicle-stimulating hormone levels were not altered by treatments, whereas melatonin was specifically increased by AZ1080. Lithium impaired mouse spontaneous locomotion and decreased amphetamine-induced hyper-locomotion. AZ1080 had no effects on locomotion, while compound A reduced spontaneous locomotor activity without effects on amphetamine-induced hyper-locomotion. The present results indicate that a broad correlation between the effects of lithium and selective GSK3 inhibitors could not be devised, suggesting alternative mechanisms, whereas overlapping results could be obtained in specific assays.
引用
收藏
页码:893 / 903
页数:11
相关论文
共 50 条
  • [1] Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system
    Laura Caberlotto
    Lucia Carboni
    Floriana Zanderigo
    Filippo Andreetta
    Michela Andreoli
    Gabriella Gentile
    Maria Razzoli
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386 : 893 - 903
  • [2] Glycogen Synthase Kinase 3 (GSK3): Its Role and Inhibitors
    Wadhwa, Pankaj
    Jain, Priti
    Jadhav, Hemant R.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2020, 20 (17) : 1522 - 1534
  • [3] A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies
    Thapa, Riya
    Gupta, Gaurav
    Bhat, Asif Ahmad
    Almalki, Waleed Hassan
    Alzarea, Sami I.
    Kazmi, Imran
    Saleem, Shakir
    Khan, Ruqaiyah
    Altwaijry, Najla
    Dureja, Harish
    Singh, Sachin Kumar
    Dua, Kamal
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2023, 253
  • [4] Identification of Glycogen Synthase Kinase-3 Inhibitors with a Selective Sting for Glycogen Synthase Kinase-3α
    Lo Monte, Fabio
    Kramer, Thomas
    Gu, Jiamin
    Anumala, Upendra Rao
    Marinelli, Luciana
    La Pietra, Valeria
    Novellino, Ettore
    Franco, Benedicte
    Demedts, David
    Van Leuven, Fred
    Fuertes, Ana
    Manuel Dominguez, Juan
    Plotkin, Batya
    Eldar-Finkelman, Hagit
    Schmidt, Boris
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (09) : 4407 - 4424
  • [5] Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic
    Medina, Miguel
    Castro, Ana
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2008, 11 (04) : 533 - 543
  • [6] Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimer's Disease
    Medina, Miguel
    Avila, Jesus
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (25) : 2790 - 2798
  • [7] Glycogen synthase kinase 3 (GSK3) inhibition: a potential therapeutic strategy for Alzheimer's disease
    Karati, Dipanjan
    Meur, Shreyasi
    Roy, Souvik
    Mukherjee, Swarupananda
    Debnath, Biplab
    Jha, Sajal Kumar
    Sarkar, Biresh Kumar
    Naskar, Saheli
    Ghosh, Priya
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, : 2319 - 2342
  • [8] Inhibition of Glycogen Synthase Kinase 3β (GSK3β) Decreases Inflammatory Responses in Brain Endothelial Cells
    Ramirez, Servio H.
    Fan, Shongshan
    Zhang, Ming
    Papugani, Anil
    Reichenbach, Nancy
    Dykstra, Holly
    Mercer, Aaron J.
    Tuma, Ronald F.
    Persidsky, Yuri
    AMERICAN JOURNAL OF PATHOLOGY, 2010, 176 (02) : 881 - 892
  • [9] Whether lithium inhibits glycogen synthase kinase (GSK)-3β activity in vivo in humans is still an open question
    Agam, Galila
    Azab, Abed N.
    BIPOLAR DISORDERS, 2016, 18 (05) : 464 - 467
  • [10] Regulation of basal gastric acid secretion by the glycogen synthase kinase GSK3
    Rotte, Anand
    Pasham, Venkanna
    Eichenmueller, Melanie
    Yang, Wenting
    Qadri, Syed M.
    Bhandaru, Madhuri
    Lang, Florian
    JOURNAL OF GASTROENTEROLOGY, 2010, 45 (10) : 1022 - 1032